Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating the Prognostic Significance of Initial PSMA PET/CT Imaging for Survival Outcomes in Synchronous Metastatic Hormone-Sensitive Prostate Cancer: A Shift in Understanding Low- versus High-Volume Disease

  • By

  • Fleur Kleiburg

  • Linda Heijmen

  • Annemieke Witteveen

  • Kiki van Duuren

  • Paul Zuidgeest

  • Frits Smit

  • Lioe-Fee de Geus-Oei

  • Tom van der Hulle

  • September 16, 2026

Share

Original Source(s)

Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease

  • by Fleur Kleiburg, Linda Heijmen, Annemieke Witteveen, Kiki van Duuren, Paul Zuidgeest, Frits Smit, Lioe-Fee de Geus-Oei, Tom van der Hulle

  • September 16, 2026

Related Content

Multi-omics profiling reveals sphingolipid metabolism reprogramming of tumor-conditioned MDSCs in cervical cancer

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors

The Pitfalls of Disproportionality Analysis: Insights on Their Interwoven Complexity and a Front-End Mitigation Strategy